Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCPED12112


NMTRC003: A Phase II Preventative Trial of DFMO (eflornithine HCI) as a Single Agent in Patients with High Risk Neuroblastoma in Remission

Principal Investigator(s)

Devang Pastakia


  • Protocol No. VICCPED12112
  • Open Date: 01/04/2013
  • Staging: Phase II
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: Correlation of urinary polyamine levels with progression of disease in neuroblastoma.
  • Disease Sites: Pediatric Solid Tumors; Neuroblastoma (Pediatrics)
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: DFMO
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01586260
  • Secondary Protocol No: NMTRC003B


None Provided.


Ages Eligible for Study:N/A to 21 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No


Inclusion Criteria:
• Age: 0-21 years at the time of diagnosis.
• Diagnosis: histologic verification at either the time of original diagnosis or a previous relapse of high risk neuroblastoma.
• Disease Status: Neuroblastoma that is in remission
• Greater than 30 days from completion of cytotoxic and biologic therapy and less than 120 days from previous therapy.
• A negative urine pregnancy test is required for female subjects of child bearing potential (onset of menses or ≥13 years of age).
• Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.
• ANC > 500/μl and platelet count >50,000/μl
• Organ Function Requirements: Subjects must have adequate liver function as defined by:
• AST and ALT <10x upper limit of normal
• Serum bilirubin must be ≤ 2.0 mg/dl
• Serum creatinine based on age/gender
• Informed Consent: All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines
Exclusion Criteria:
• Lansky score < 60%
• BSA (m2) of <0.25
• Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.
• Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects).
• Infection: Subjects who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.
• Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.